Skip to content
Peptigraph home

CagriSema

Amylin + GLP-1 combination. CagriSema is investigational and not approved for any use.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated Strongest evidence: Human RCT evidence, 4 of 4
StatusInvestigational · filed with FDAProhibited by WADA (S0)Full legal history

Key facts

Class
Amylin + GLP-1 combination
Also called
No common aliases
Half-life
159-195 h (with semaglutide 2.4 mg co-administered)
subcutaneous, in people · Lancet 2021, PMID 33894838
FDA status
Not approved
Investigational · filed with FDA
WADA
Prohibited (S0)
In and out of competition
Everything on CagriSema

CagriSema guides

Researched for

Evidence at a glance

Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies.

CagriSema: studies by condition
ConditionHuman studiesAnimal studiesStudies we summarisedEvidence grade
Weight lossNot in our ledgerNot in our ledger10Human RCT evidence, 4 of 4The lancet. Diabetes & endocrinology 2026, PMID 42009015
DiabetesNot in our ledgerNot in our ledger6Human RCT evidence, 4 of 4The lancet. Diabetes & endocrinology 2026, PMID 42251860
Heart healthNot in our ledgerNot in our ledger2Human RCT evidence, 4 of 4Hypertension 2026, PMID 41328546
MetabolismNot in our ledgerNot in our ledger5Human RCT evidence, 4 of 4The lancet. Diabetes & endocrinology 2026, PMID 42251860

Grades follow our evidence scale. Summarised studies come from our evidence file, each quote checked against the abstract or label.

CagriSema is two drugs in one weekly injection

CagriSema is the name used for the combination of semaglutide and cagrilintide.[7]

In the phase 1b trial of cagrilintide given alongside semaglutide, cagrilintide's half-life was 159-195 h.[4]

Strongest finding and what it is compared with

In the main obesity trial, mean weight change was -20.4% with the combination against -3.0% with placebo.[7]

In a trial against semaglutide alone, weight change at week 68 was -18.4% on the combination and -11.9% on semaglutide (estimated difference -6.5 percentage points).[3]

In people with type 2 diabetes, the weight change was -13.7% on the combination and -3.4% on placebo.[8]

Gastrointestinal adverse events affected 79.6% on the combination and 39.9% on placebo in the main trial.[7]

REIMAGINE 3 added CagriSema to basal insulin in adults with type 2 diabetes. HbA1c fell by 2.33 percentage points on the 2.4 mg pairing and 2.10 on the 1.0 mg pairing, against 0.66 on placebo at week 40.[9]

Regulatory path

Drugs@FDA lists no CagriSema product.[2]

CagriSema is not on WADA's named list. The S0 clause covers unapproved drugs still in clinical development.[1]

Common questions

Is CagriSema FDA approved?

No. CagriSema is investigational (investigational · filed with fda) and not approved for any use.

Is CagriSema banned in sport?

Yes. Prohibited by WADA (S0), so it is prohibited at all times for tested athletes.

What is CagriSema?

The name for the combination of cagrilintide and semaglutide.[7]

What are the CagriSema clinical trials?

The main obesity trial reported a mean weight change of -20.4% versus -3.0% on placebo.[7]

How does CagriSema work?

It combines two drugs: cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 analogue.[4]

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2United States: No FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "cagrisema" returned no matches on 2 Oct 2026.U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  3. 3Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.The lancet. Diabetes & endocrinology · 2026PMID 42009015Accessed 2 Oct 2026
  4. 4Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.Lancet (London, England) · 2021PMID 33894838Accessed 2 Oct 2026
  5. 5Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.The lancet. Diabetes & endocrinology · 2026PMID 42251860Accessed 2 Oct 2026
  6. 6CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.Hypertension (Dallas, Tex. : 1979) · 2026PMID 41328546Accessed 2 Oct 2026
  7. 7Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.The New England journal of medicine · 2025PMID 40544433Accessed 2 Oct 2026
  8. 8Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.The New England journal of medicine · 2025PMID 40544432Accessed 2 Oct 2026
  9. 9Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.Lancet (London, England) · 2026PMID 42251856Accessed 2 Oct 2026

Found an error? Report a correction.